• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒病的病理生理学及以宿主为中心的方法

Pathophysiology of Covid-19 and host centric approaches in .

作者信息

Pandkar Prasad Dilip, Sachdeva Vinay

机构信息

Department of Kriya Sharir (Ayurveda Physiology), Bharati Vidyapeeth Deemed University, College of Ayurveda, Pune, India.

Department of Kriya Sharir (Ayurveda Physiology), Bharati Vidyapeeth Deemed University, College of Ayurveda, Pune, India.

出版信息

J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100380. doi: 10.1016/j.jaim.2020.11.010. Epub 2020 Dec 2.

DOI:10.1016/j.jaim.2020.11.010
PMID:33519134
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833327/
Abstract

The world is facing a global crisis and health emergency of COVID-19. Understanding of COVID-19 pathophysiology in ayurvedic host centric framework is prerequisite for apt use of . This paper reviews COVID-19 pathophysiology, clinical presentations and prognosis in ayurvedic perspective. Concept of exogenous pathogenic diseases can be traced in fever, microbes, toxins, epidemics and seasonal regimens chapters of Such exogenous diseases later manifest multi-system presentation according to involvement of different ' and derangement of '. The pathology of COVID-19 is primarily that of (fever) with involvement of respiratory system. Secondary manifestations include coagulopathies, cardiovascular, neural, and renal complications. Gastrointestinal system is closely associated with respiratory mechanism in pathophysiological conceptualization of . Abnormal immune responses in COVID-19 are result of abnormalities of , (blood) and (Vital nectar). The initial phase is dominant whereas later stage of aggravated immune response is dominant. Alveolar damage, coagulopathies indicate vitiation. With this integrative understanding of COVID-19, we propose novel strategies for therapeutics and prophylaxis. Measures for 'Conservation of , 'Attainment of homeostasis and 'Protection of i.e. vital organs' can be important Host based strategies for reduction in the mortality in COVID-19 and for better clinical outcomes. This host centric approach can make paradigm shift in management of this epidemic.

摘要

世界正面临着新冠病毒的全球危机和健康紧急情况。在阿育吠陀以宿主为中心的框架内理解新冠病毒的病理生理学是恰当使用[相关内容]的先决条件。本文从阿育吠陀的角度综述了新冠病毒的病理生理学、临床表现和预后。外感致病疾病的概念可在[相关典籍]的发热、微生物、毒素、流行病和季节养生章节中找到。此类外感疾病随后根据不同的“[相关概念1]”受累情况和“[相关概念2]”紊乱情况表现出多系统症状。新冠病毒的病理学主要是伴有呼吸系统受累的“[相关概念3]”(发热)。次要表现包括凝血功能障碍、心血管、神经和肾脏并发症。在阿育吠陀的病理生理学概念中,胃肠道系统与呼吸机制密切相关。新冠病毒中异常的免疫反应是“[相关概念4]”、“[相关概念5]”(血液)和“[相关概念6]”(生命之液)异常的结果。初始阶段以“[相关概念7]”为主导,而免疫反应加重的后期阶段以“[相关概念8]”为主导。肺泡损伤、凝血功能障碍表明“[相关概念9]”受损。基于对新冠病毒的这种综合理解,我们提出了治疗和预防的新策略。“保护‘[相关概念10]’”、“实现‘[相关概念11]’内环境稳定”和“保护‘[相关概念12]’即重要器官”的措施可能是基于宿主的重要策略,可降低新冠病毒的死亡率并获得更好的临床结果。这种以宿主为中心的方法可在该流行病的管理中带来范式转变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/52ba6aa792c1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/b874fdb68ac1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/a9b5def0d1b7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/52ba6aa792c1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/b874fdb68ac1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/a9b5def0d1b7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea0e/8724882/52ba6aa792c1/gr3.jpg

相似文献

1
Pathophysiology of Covid-19 and host centric approaches in .新冠病毒病的病理生理学及以宿主为中心的方法
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100380. doi: 10.1016/j.jaim.2020.11.010. Epub 2020 Dec 2.
2
Understanding hypertension in the light of Ayurveda.从阿育吠陀医学角度理解高血压。
J Ayurveda Integr Med. 2018 Oct-Dec;9(4):302-307. doi: 10.1016/j.jaim.2017.10.004. Epub 2017 Nov 17.
3
Development and standardization of Mysore Tridosha scale.迈索尔三体液量表的开发与标准化
Ayu. 2011 Jul;32(3):308-14. doi: 10.4103/0974-8520.93905.
4
Prakriti Analysis of COVID 19 Patients: An Observational Study.COVID-19 患者的体质分析:一项观察性研究。
Altern Ther Health Med. 2021 Jun;27(S1):12-17.
5
Management of w.s.r to COVID-19 - Case report.新型冠状病毒肺炎相关白塞病的管理——病例报告
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100416. doi: 10.1016/j.jaim.2021.02.007. Epub 2021 Mar 6.
6
Principle of Hot (Ushna) and Cold (Sheeta) and Its Clinical Application in Ayurvedic Medicine.热(乌莎那)和冷(希塔)的原则及其在阿育吠陀医学中的临床应用。
Adv Exp Med Biol. 2021;1343:39-55. doi: 10.1007/978-3-030-80983-6_4.
7
Hypothalamic digoxin, hemispheric chemical dominance, and the tridosha theory.下丘脑地高辛、半球化学优势与三体液学说
Int J Neurosci. 2003 May;113(5):657-81. doi: 10.1080/00207450390200017.
8
An Ayurvedic personalized prophylactic protocol in COVID-19.一种针对新冠肺炎的阿育吠陀个性化预防方案。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100351. doi: 10.1016/j.jaim.2020.08.004. Epub 2020 Sep 8.
9
Multimodal ayurvedic approach in the management of moderate SARS-COV2 infection with co-morbidities - A case report.多模式阿育吠陀疗法治疗合并症的中度SARS-CoV2感染——病例报告
J Family Med Prim Care. 2022 Jan;11(1):344-349. doi: 10.4103/jfmpc.jfmpc_495_21. Epub 2022 Jan 31.
10
Ayurvedic treatment of COVID-19: A case report.阿育吠陀疗法治疗新冠肺炎:一例病例报告。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100329. doi: 10.1016/j.jaim.2020.06.001. Epub 2020 Jun 19.

引用本文的文献

1
Pharmacoinformatics in identifying therapeutically important chemical species from Ayurvedic formulations employed in treating COVID-19 patients.药物信息学在从用于治疗新冠肺炎患者的阿育吠陀配方中识别具有治疗重要性的化学物质方面的应用。
J Ayurveda Integr Med. 2025 Jun 23;16(4):101161. doi: 10.1016/j.jaim.2025.101161.
2
Acute urinary retention following frequent administration of Guggulu Tiktakam Kwatha and its management - a case report.频繁服用古古卢提卡姆夸塔后急性尿潴留及其处理——病例报告
J Ayurveda Integr Med. 2025 Mar-Apr;16(2):101086. doi: 10.1016/j.jaim.2024.101086. Epub 2025 Mar 28.
3
Evaluating Personalized Add-On Ayurveda Therapy in Oxygen-Dependent Diabetic COVID-19 Patients: A 60-Day Study of Symptoms, Inflammation, and Radiological Changes.
评估个性化阿育吠陀辅助疗法对依赖氧气的糖尿病COVID-19患者的疗效:一项关于症状、炎症和影像学变化的60天研究
Cureus. 2024 Sep 1;16(9):e68392. doi: 10.7759/cureus.68392. eCollection 2024 Sep.
4
Treatment of the common cold with herbs used in Ayurveda and Jamu: monograph review and the science of ginger, liquorice, turmeric and peppermint.阿育吠陀和爪哇草药治疗普通感冒:专著综述以及生姜、甘草、姜黄和薄荷的科学研究
Drugs Context. 2023 Jun 14;12. doi: 10.7573/dic.2023-2-12. eCollection 2023.
5
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.AYUSH 64 联合标准治疗用于轻中度 COVID-19 的辅助治疗:一项随机、对照、多中心临床试验。
PLoS One. 2023 Mar 16;18(3):e0282688. doi: 10.1371/journal.pone.0282688. eCollection 2023.
6
COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation.一名合并B细胞淋巴瘤的COVID-19患者通过联合使用阿育吠陀配方药物进行治疗。
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100632. doi: 10.1016/j.jaim.2022.100632. Epub 2022 Aug 12.
7
Phytochemicals as potential inhibitors for COVID-19 revealed by molecular docking, molecular dynamic simulation and DFT studies.通过分子对接、分子动力学模拟和密度泛函理论研究揭示植物化学物质作为COVID-19的潜在抑制剂
Struct Chem. 2022;33(5):1423-1443. doi: 10.1007/s11224-022-01982-4. Epub 2022 Jun 13.
8
Immune-based therapeutic approaches in COVID-19.COVID-19 的免疫治疗方法。
Biomed Pharmacother. 2022 Jul;151:113107. doi: 10.1016/j.biopha.2022.113107. Epub 2022 May 16.
9
A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India.一项在印度专门的新冠医院(DCH)中进行的随机、对照、双盲、平行分组临床试验,旨在研究 Ayurcov(AyurCoro3)一日疗程作为 COVID-19 疾病管理辅助疗法的作用。
Complement Ther Med. 2022 Aug;67:102824. doi: 10.1016/j.ctim.2022.102824. Epub 2022 Mar 25.
10
Ayurvedic management of pregnant woman infected with SARS-CoV-2 - A case report.感染新型冠状病毒肺炎的孕妇的阿育吠陀疗法——病例报告
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100423. doi: 10.1016/j.jaim.2021.03.005. Epub 2021 Jun 15.